Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.54
-0.0500-1.93%
Post-market: 2.560.0240+0.94%19:56 EDT
Volume:25.66K
Turnover:65.85K
Market Cap:25.34M
PE:-0.58
High:2.62
Open:2.59
Low:2.51
Close:2.59
52wk High:19.35
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:0.27
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3427
EPS(LYR):-4.0377
ROE:-89.23%
ROA:-50.69%
PB:0.94
PE(LYR):-0.63

Loading ...

Atossa Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Atossa Therapeutics Inc Expected to Post a Loss of $1.08 a Share - Earnings Preview

Reuters
·
Aug 07

Atossa Therapeutics Q2 Operating Income USD -8.7 Million

THOMSON REUTERS
·
Aug 07

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 07

Atossa Therapeutics Q2 Net Loss Widens to $18.1 Million; Reports no Revenue

Reuters
·
Aug 07

Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer

TIPRANKS
·
Jul 31

Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action

TIPRANKS
·
Jul 28

Atossa Says Novel Endoxifen-related Compounds Show Potent Preclinical Activity in ER-positive Breast Cancer Models

Reuters
·
Jul 28

Atossa Therapeutics Announces AACR Poster Presentation on (z)-endoxifen in Mccune-albright Syndrome

Reuters
·
Jul 21

Atossa Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Jul 08

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jul 07

Atossa Therapeutics closes registered direct offering raising USD 4.5 million upfront

Reuters
·
Jun 13

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 13

Top Midday Decliners

MT Newswires Live
·
Jun 12

Atossa Therapeutics Launches $16.5 Million Registered Direct Offering

MT Newswires Live
·
Jun 11

Atossa Therapeutics issues Series A and B warrants for 1,363,638 shares in registered direct offering at $3.3 each

Reuters
·
Jun 11

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 11

Atossa says Phase 2 EVANGELINE trial tests (Z)-endoxifen plus goserelin in premenopausal ER+/HER2- breast cancer

Reuters
·
May 27

Atossa Therapeutics Announces Asco 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across Esr1 Mutations and Ongoing Evangeline Phase 2 Trial

THOMSON REUTERS
·
May 27

Atossa says (Z)-endoxifen Duchenne muscular dystrophy review accepted for publication

Reuters
·
May 21